Maravai LifeSciences (MRVI) Stock
Key stats
- Market cap
- $1.15B
- Price / Earnings ratio
- -31.1x
- EPS (TTM)
- -$0.43
- Volume
- Loading
- 52-week high
- $9.42
- 52-week low
- $2.80
Source: third-party data provider, as of November 13, 2026
Compare with MRVI
Recent news

Maravai LifeSciences Announces November 2026 Investor Conference Schedule
Maravai LifeSciences Announces November 2026 Investor Conference Schedule
MRVI

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
MRVI

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
MRVI

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
MRVI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.68
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.09
- MACD histogram
- 0.01
- SMA 50
- $7.39
- Price above SMA 50
- EMA 50
- $7.37
- Price above EMA 50
- SMA 200
- $5.39
- Price above SMA 200
- EMA 200
- $5.62
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.10 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Maravai LifeSciences Announces November 2026 Investor Conference Schedule
Maravai LifeSciences Announces November 2026 Investor Conference Schedule
MRVI

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
MRVI

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
MRVI

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
MRVI

Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences Q2 Earnings Call Highlights
MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
MRVI

Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
MRVI

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
MRVI

TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
MRVI

TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
MRVI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Bernd Brust | CEO & Director | 1967 |
| Mr. Robert Andrew Eckert M.B.A. | Chairman of the Board | 1962 |
| Mr. Rajesh J. Asorpota | EVP & Chief Financial Officer | 1967 |
| Mr. Kurt A. Oreshack J.D. | Executive VP, General Counsel & Secretary | 1981 |
| Ms. Christine Dolan | Executive VP & GM of Cygnus Technologies | 1968 |
| Ms. Chanfeng Zhao | Senior VP & Chief Scientific Officer | — |
| Ms. Debra Hart | Senior Director of Investor Relations | — |
| Ms. Judith A. Solecki | Senior VP & Chief Human Resources Officer | — |
| Dr. Kate E. Broderick Ph.D. | Executive Vice President | — |
| Mr. Christopher C. Benoit | Executive VP & Advisor | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.68
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.09
- MACD histogram
- 0.01
- SMA 50
- $7.39
- Price above SMA 50
- EMA 50
- $7.37
- Price above EMA 50
- SMA 200
- $5.39
- Price above SMA 200
- EMA 200
- $5.62
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +24.3 | -3.5 | ||||||||||
| 2022 | -27.3 | +31.2 | -10.6 | -12.9 | +1.6 | -9.9 | -11.3 | -18.4 | +22.0 | -33.0 | -9.4 | -0.6 |
| 2023 | +7.1 | -2.6 | -6.4 | +1.7 | -5.8 | -5.6 | -9.1 | -6.3 | -2.9 | -29.2 | -24.0 | +22.0 |
| 2024 | -13.9 | +43.7 | +14.2 | -4.7 | +3.0 | -18.2 | +40.2 | -6.0 | -4.8 | -8.0 | -24.0 | -5.1 |
| 2025 | -10.2 | -34.8 | -26.8 | -6.5 | +10.8 | +13.1 | -6.8 | +9.0 | +21.1 | +0.0 | +23.1 | -3.8 |
| 2026 | -1.2 | +5.6 | -21.6 | +28.2 | +28.7 | +31.4 | +6.8 | +19.0 | +4.9 | +4.1 | +7.1 |



